Performance Comparison of the 25 Gauge 20,000cpm HYPERVIT Dual Blade vs. 10,000cpm ULTRAVIT Vitrectomy Cutter

NCT05710458 — Not applicable, Completed, 72 participants, The University of Hong Kong

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT05710458
StatusCompleted
PhaseNot applicable
Study typeInterventional; randomized, parallel, masking: single, treatment
Enrollment72 (Actual)
SponsorThe University of Hong Kong (Other)
ConditionsVitrectomy, Epiretinal Membrane, Macular Hole, Vitreous Hemorrhage, Retinal Detachment
Interventions25 gauge 20,000 cpm Hypervit Dual Blade, 25 gauge 10,000 cpm Ultravit Vitrectomy Cutter (Device)
Datesstart 2021-07-01, primary completion 2022-10-12, completion 2022-11-30, first posted 2023-02-02, last updated 2023-02-02
Locations1 site in Hong Kong

Related Papers Related Patents Related Grants Related Experts
All trials for Vitrectomy All trials for Epiretinal Membrane All trials of 25 gauge 20,000 cpm Hypervit Dual Blade All trials of 25 gauge 10,000 cpm Ultravit Vitrectomy Cutter

-Summary

This prospective randomised controlled trial will be conducted to investigate that increasing the vitrectomy cutting rate from 10,000 cut/min to 20,000 cut/min will result more efficiency and shorter core vitrectomy time, and it is equally safe as compared to the current 10,000 cut/min. We plan to target the patients undergoing for vitrectomy for common vitreoretinal pathology. Our plan is to conduct a randomised study with 2 arms, one with the higher cutting rate (20,000 cut/min) versus a second arm using the existing system 10,000 cuts/min.

Expand all sections  ·  Collapse all

+Detailed description

In addition, we will measure the core vitrectomy duration by Constellation Vision System stopwatch. We will count the duration when the vitrectomy probe enter into the eye to the moment the performing the air/fluid exchange by shaving the peripheral vitreous to complete the vitrectomy. For our second outcome measure to prove the no-inferiority of intraoperative and postoperative complications patients will have 3 months follow up visits.

+Arms and interventions

ArmTypeInterventionsDescription
25 gauge 20,000 cpm Hypervit Dual BladeExperimentalDevice: 25 gauge 20,000 cpm Hypervit Dual BladeNew vitrectomy blade with higher cutting rate
25 gauge 10,000 Ultravit vitrectomy cutterActive comparatorDevice: 25 gauge 10,000 cpm Ultravit Vitrectomy CutterExisting vitrectomy blade with cutting rate 10,000 cut/min
  • 25 gauge 20,000 cpm Hypervit Dual Blade (Device), also known as 20K: Vitrectomy blade with increased cutting rate to 20,000 cut/min
  • 25 gauge 10,000 cpm Ultravit Vitrectomy Cutter (Device), also known as 10K: Existing Vitrectomy blade with cutting rate 10,000 cut/min

+Outcome measures

Primary outcomes

  • Duration of Core vitrectomy [intraoperative (From the moment probe enter into the eye till performing the air/fluid exchange to complete the vitrectomy)]: Measurement of core vitrectomy duration by Constellation Vision System

Secondary outcomes

  • Non-inferiority of intraoperative and postoperative complication [3 months]: Safety and Efficacy

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Patient over 18 years of age who are undergoing vitrectomy for the following conditions:

  * Macular hole
  * Epimacular membrane
  * Vitreous hemorrhage
  * Primary retinal detachment

Exclusion Criteria:

* Patient who is

  * unable to give proper consent
  * previous vitrectomy or scleral buckle surgery
  * cases requiring silicone oil tamponed
  * undergoing repeated retinal detachment surgery
  * undergoing surgery for tractional diabetic retinopathy

+Locations (1)

FacilityCityCountryStatus
Grantham HospitalHong KongHong Kong

+Publications

  • O'Malley C, Heintz RM Sr. Vitrectomy with an alternative instrument system. Ann Ophthalmol. 1975 Apr;7(4):585-8, 591-4. PMID 1147502
  • Rizzo S, Genovesi-Ebert F, Belting C. Comparative study between a standard 25-gauge vitrectomy system and a new ultrahigh-speed 25-gauge system with duty cycle control in the treatment of various vitreoretinal diseases. Retina. 2011 Nov;31(10):2007-13. doi: 10.1097/IAE.0b013e318213623a. PMID 21685823